The company has a strong proprietary and Intellectual Property position covering both Miltuximab®, its anti-GPC-1 antibody and the antigen itself, GPC-1. This provides robust and long-term protection for the commercialization of important new treatments to people with little hope of
– The ability to address a clear market need for new therapies to target solid tumors.
– A clear development pathway.
– A clear understanding of the requirements for the pipeline development programs.
– The leadership team needed to manage the planned research programs.
– A clear end goal which is to maximize the return on its intellectual property assets.
Miltuximab® (our patented antibody) targets Glypican-1 (GPC-1), a protein overexpressed in prostate, pancreatic, bladder, esophageal and other solid tumors. We have commenced a first in
For any antibody-based therapy one should not only be the first but also the best in class. To achieve this GlyTherix is developing pipeline with:
- The best version of the antibody; which is most effective and safe as well as acceptable to our future licensee partners.
- The best
cell killingpayload; which is most effective and well tolerated by the patient.
The company has also developed Glytuzumab® a humanized antibody targeting GPC-1.
Miltuximab® for Therapeutics and Imaging
Our patented antibody targets Glypican-1 (GPC-1), a protein overexpressed in prostate, pancreatic, bladder, esophageal and other solid tumors.
We have commenced a first in
The MILGa Cancer Imaging Trial is a first-in-human study to evaluate the safety and tumor targeting of Miltuximab® in patients with advanced prostate, bladder and pancreatic cancer. Preclinical studies have demonstrated that Miltuximab® accurately targets prostate, pancreatic and bladder cancer cells, and is well-tolerated and highly specific in mouse models of prostate cancer.
The trial being conducted at the Macquarie University Hospital also involves experts from the Australian Nuclear Science and Technology Organisation (ANSTO), Catalent, AusPep, and Southern Star Research. Read more >
In October 2016 the Company announced the start of our
In addition to radiotherapy, GlyTherix is looking at other mechanisms of action using Miltuximab®
Global research collaborations
- The Centre for Advanced Imaging at the University of Queensland
- The Australian Prostate Cancer Research Centre at the Queensland University of Technology
- The IDEAL Hub,
Universityof Technology Sydney and University of South Australia
- The Division of Urologic Oncology at the University of Michigan Medical School
- Molecular Imaging Innovations Institute at Weill Cornell Medical College New York